Walid Macaron, MD MSc

PGY-3 @BCM_InternalMed • Former Researcher @MDAndersonNews Leukemia Dpt • MD, MSc in Genetics and Molecular Biology @USJLiban • #GGMU • 🇱🇧

[Walid Macaron, MD MSc @WNMacaron]

An incredible experience presenting our work at #ASH24!
Truly grateful for the guidance and support from the best mentor @NicholasShortMD.

[Walid Macaron, MD MSc @WNMacaron]

@NicholasShortMD @DrHKantarjian

#LeuSM #ALL #ALLsm #CLML

https://t.co/TvhdHkgIm0

[Walid Macaron, MD MSc @WNMacaron]

Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras.
Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉We are super proud to welcome our newest class of Heme/Onc Fellow MDs to @MDAndersonNews !!! 📣 Congratulations! @KellyMezaMD @HannahGoulart @JenMarvinPeek @lungoncdoc @VanMorrisMD @homesforhealers @marklewismd @Daver_Leukemia @mtmdphd | #MatchDay #Fellowship #meded

[Walid Macaron, MD MSc @WNMacaron]

A dream come true. Absolutely thrilled to have matched at @MDAndersonNews for heme/onc fellowship. Grateful for my incredible support system, the mentors who shaped my path, and my training at @BCM_InternalMed.

#FellowMatch

[Eric K. Singhi, MD @lungoncdoc]

Thrilled to congratulate everyone on Match Day, especially the newly matched @MDAndersonNews Hematology & Medical Oncology Fellowship Class of 2029! #EndCancer

[Walid Macaron, MD MSc @WNMacaron]

• HR Ph- ALL who achieved early NGS MRD neg→favorable long-term survival

• HR Ph- ALL and suboptimal MRD dynamics→poor outcomes and benefitted from alloSCT in first remission

• Early NGS MRD dynamics can refine risk stratification and may guide consolidative tx decisions

[Walid Macaron, MD MSc @WNMacaron]

Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.

https://t.co/uR43j02ClQ

@NicholasShortMD @DrHKantarjian
#Leusm #ALLsm

[Lewis Nasr @lewisnasr]

Our team won the @SocietyofHemOnc Honorable Distinction award for our poster submission on the prognostic impact of NGS MRD in Ph- ALL! Special thanks to @NicholasShortMD @WNMacaron @DrHKantarjian

[Fadi Haddad, MD @FadiHaddad_MD]

Survival of adult #ALL is significantly better 👍

‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontline & salvage

‼️ Ph➕ ALL: Chemotherapy-free approach improves survival & spares transplant

#leusm @DrHKantarjian @SocietyofHemOnc @OncoAlert

[Hagop Kantarjian,MD @DrHKantarjian]

Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@MDAndersonNews #Leukemia
https://t.co/eQLDCAbR4H
#leusm

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

Our ⁦@TXMedCenter⁩ before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Houston is the world’s largest, and also the first biomedicine city of >100,000 employees, >60 institutions, including several medical schools

[Rafeh Naqash, MD, FASCO @thenasheffect]

‼️Only data so far of ICI in pts with cardiac Mets. Work led by @AminNassarMD @sarahaboualaiwi @TalalZarif1 out in @jitcancer . A collaboration that spanned several countries and centers. @OUCollegeofMed @StephensonCC
@DrChoueiri

https://t.co/NcnmEnozSb

[OncoAlert @OncoAlert]

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC

https://t.co/xmNYDEgSY0

This retrospective, multicenter study examined the safety and clinical outcomes of 110 patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs). The most common cancers were #melanoma (38%) and non-small cell lung cancer #NSCLC (24%), with cardiac metastases frequently located in the atria and ventricles. Cardiac events occurred in 36% of patients, but ICI-related major cardiac adverse events were rare (1.8%). Treatment-related adverse events (trAEs) were common, with 20% experiencing severe (grade ≥3) trAEs. Patients with multiple cardiac metastases had lower response rates to ICI-based therapies.

Overall, ICIs showed meaningful efficacy, particularly in melanoma, with no increase in safety risks, highlighting the importance of multidisciplinary management in these complex cases.

@AminNassarMD
@sarahaboualaiwi
@TalalZarif1
@RyanDenu
@WNMacaron
@Dory_Freeman
@Avasbind
@salimhayek
@ShirlyGrynberg
@jennkwanMDPhD
@ProfGLongMIA
@TarekHaykal1
@Atandondoc
@nakhtermd
@datsunian
@EdwardElAmm
@eliekozaily1
@ahmadalhader
@boufarhat_elias
@mer_herreraMD
@chulkimMD
@kaushalpar
@ADesaiMD
@ACortelliniMD
@DJPinato
@JamesKz_
@nerealiamd
@FunchainMD
@AChoudharyMD
@AartiAsnaniMD
@navstruck
@ja_ocejo
@JTrentMDPhD
@DrRanaMcKay
@TomasNeilan
@DrChoueiri
@thenasheffect

[Toni Choueiri, MD @DrChoueiri]

Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis.

https://t.co/PeDTs6nsG5

@thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber

[ALL Hub @ALL_Hub_]

CONGRESS #ASH24 | PRESENTATION
@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: https://t.co/fDCz3La5Dx
#ALL #ALLsm

[JACC Journals @JACCJournals]

Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. https://t.co/Clz7NnoTWw

#JACCCardioOnc #CardioOnc #Immunotherapy @AminNassarMD

[Bonnie Ky, MD, MSCE, FACC @DrBonnieKy]

🫀Don't miss this original research from a great team in @JACCJournals! 📰https://t.co/BEioy54ozI

@AminNassarMD @DrChoueiri @DrSarcoma @TomasNeilan @ADesaiMD @hannadallapria @RyanDenu #JACCCardioOnc

[UT MD Anderson @UTMDAnderson]

Adding gilteritinib to azacitidine and venetoclax shows improved outcomes in patients with FLT3-mutated acute myeloid leukemia, according to a study led by MD Anderson researchers. https://t.co/6zAT5lu8u2 @NicholasShortMD @DrHKantarjian @Daver_Leukemia @TapKadia #AML #EndCancer

[Nicholas Short MD @NicholasShortMD]

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at @JCO_ASCO
In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven)
Could be delivered safely with appropriate dose modifications.
https://t.co/JZmsMproiW

[Hagop Kantarjian,MD @DrHKantarjian]

Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population.
@NicholasShortMD of @MDAndersonNews #Leukemia
https://t.co/xogxmfAy74 @JCO_ASCO
#leusm